Thursday, September 27, 2012

NEJM: Overly Defensive, or Just Naive?

›
The Sept. 20 issue of the New England Journal of Medicine featured a study ( http://www.nejm.org/doi/full/10.1056/NEJMsa1202397 ) by Dr. Aa...
6 comments:
Wednesday, September 26, 2012

More on Tamiflu: The Challenges of Getting Good Evidence

›
I posted some time back on oseltamivir (Tamiflu) and the Cochrane systematic review that concluded that there's no good evidence that th...
1 comment:
Tuesday, September 25, 2012

Another Example of Industry Spreading Non-Facts: Health Information Technology

›
While I try not to tread on the territory of our friends over at the Health Care Renewal blog, and keep this blog devoted to pharmaceutical ...
2 comments:
Wednesday, September 12, 2012

Inverse Benefit in the Trenches: Primary Care Providers Treat Chronic Illness

›
My esteemed anthropologist colleague, Dr. Linda M. Hunt, and her graduate student Meta Kreiner at Michigan State University set out to do a ...
3 comments:

From the Belly of the Beast: The Future of Drug Reps

›
"Dear Howard," begins the e-mail, "here at Cutting Edge Information, we have done extensive primary research about some of th...
Monday, September 10, 2012

China and Unsafe Drugs--Any Progress Made?

›
I have in the past blogged about drug safety issues with U.S. companies buying critical drug ingredients from unregulated and uninspected Ch...
3 comments:

Ethics (or Lack Thereof) and Post-Marketing Studies

›
As I noted in HOOKED, and as has been here documented, all too often the FDA approves a new drug contingent upon the company doing a post-ma...